RLYB Stock Analysis
RL
Uncovered
Rallybio Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Rallybio Corporation is a clinical-stage biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering therapies that improve the lives of patients suffering from severe and rare diseases. It offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. It provides RLYB211, a polyclonal anti-HPA-1a antibody. Its RLYB211 is in Phase I/II clinical trial. The Company’s lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody. It is also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and ophthalmic disorders. Its RLYB116 is a long-acting, subcutaneously administered inhibitor of complement factor 5 (C5) in development for the treatment of patients with PNH and gMG. It also includes RLYB114, which is a pegylated C5 inhibitor.